This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Antitrust litigation - Zydus Pharmaceuticals - Cadila Healthcare - Gilead Sciences

Zydus Pharmaceuticals and Cadila Healthcare filed a complaint against Gilead Sciences for allegedly engaging in anticompetitive behavior aimed at keeping generic versions of its pulmonary hypertension drug Letairis off the market. The complaint alleges that Gilead has refused to provide samples of Letairis, preventing Zydus from performing the bioequivalence testing required to obtain US Food and Drug Administration approval for its generic under the Letairis Risk Evaluation and Mitigation Strategy Program developed by Gilead. 

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login